Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 16,584Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Kuvan

PharmaCompass

01

Brand Name : Kuvan

Sapropterin Dihydrochloride

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Kuvan

arrow
2024 ACI Convention
Not Confirmed

Sapropterin Dihydrochloride

Main Therapeutic Indication : Nephrology

Currency : USD

2020 Revenue in Millions : 458

2019 Revenue in Millions : 463

Growth (%) : -1

blank

02

Brand Name : Kuvan

Sapropterin Dihydrochloride

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Kuvan

arrow
2024 ACI Convention
Not Confirmed

Sapropterin Dihydrochloride

Main Therapeutic Indication : Nephrology

Currency : USD

2021 Revenue in Millions : 286

2020 Revenue in Millions : 458

Growth (%) : -38

blank

03

Brand Name : Kuvan

Sapropterin Dihydrochloride

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Kuvan

arrow
2024 ACI Convention
Not Confirmed

Sapropterin Dihydrochloride

Main Therapeutic Indication : Genetic Diseases

Currency : USD

2022 Revenue in Millions : 228

2021 Revenue in Millions : 286

Growth (%) : -20

blank

04

Brand Name : Kuvan

Sapropterin Dihydrochloride

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Kuvan

arrow
2024 ACI Convention
Not Confirmed

Sapropterin Dihydrochloride

Main Therapeutic Indication : Genetic Diseases

Currency : USD

2023 Revenue in Millions : 181

2022 Revenue in Millions : 228

Growth (%) : -21

blank

05

Brand Name : Kuvan

Sapropterin Dihydrochloride

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Kuvan

arrow
2024 ACI Convention
Not Confirmed

Sapropterin Dihydrochloride

Main Therapeutic Indication : Hyperphenylalaninemia

Currency : USD

2017 Revenue in Millions : 408

2016 Revenue in Millions : 348

Growth (%) : 17

blank

06

Brand Name : Kuvan

Sapropterin Dihydrochloride

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Kuvan

arrow
2024 ACI Convention
Not Confirmed

Sapropterin Dihydrochloride

Main Therapeutic Indication : Renal Disorders

Currency : USD

2018 Revenue in Millions : 434

2017 Revenue in Millions : 408

Growth (%) : 6%

blank

07

Brand Name : Kuvan

Sapropterin Dihydrochloride

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Kuvan

arrow
2024 ACI Convention
Not Confirmed

Sapropterin Dihydrochloride

Main Therapeutic Indication : Nephrology

Currency : USD

2019 Revenue in Millions : 463

2018 Revenue in Millions : 434

Growth (%) : 7

blank